Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 170

1.

Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study.

Sjögren V, Byström B, Renlund H, Svensson PJ, Oldgren J, Norrving B, Själander A.

PLoS One. 2017 Jul 10;12(7):e0181000. doi: 10.1371/journal.pone.0181000. eCollection 2017.

2.

An integrated epidemiological and neural net model of the warfarin effect in managed care patients.

Jacobs DM, Stefanovic F, Wilton G, Gomez-Caminero A, Schentag JJ.

Clin Pharmacol. 2017 May 18;9:55-64. doi: 10.2147/CPAA.S136243. eCollection 2017.

3.

Stroke in Patients with Chronic Kidney Disease…: How do we Approach and Manage it?

Nayak-Rao S, Shenoy MP.

Indian J Nephrol. 2017 May-Jun;27(3):167-171. doi: 10.4103/0971-4065.202405. Review.

4.

Time in Therapeutic Range and Outcomes After Warfarin Initiation in Newly Diagnosed Atrial Fibrillation Patients With Renal Dysfunction.

Szummer K, Gasparini A, Eliasson S, Ärnlöv J, Qureshi AR, Bárány P, Evans M, Friberg L, Carrero JJ.

J Am Heart Assoc. 2017 Mar 1;6(3). pii: e004925. doi: 10.1161/JAHA.116.004925.

5.

Epidemiology, Risk Factors, and Clinical Features of Intracerebral Hemorrhage: An Update.

An SJ, Kim TJ, Yoon BW.

J Stroke. 2017 Jan;19(1):3-10. doi: 10.5853/jos.2016.00864. Epub 2017 Jan 31. Review.

6.

Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis.

Bundhun PK, Soogund MZ, Teeluck AR, Pursun M, Bhurtu A, Huang WQ.

BMC Cardiovasc Disord. 2017 Jan 6;17(1):15. doi: 10.1186/s12872-016-0449-2. Review.

7.

Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation With Direct Oral Anticoagulants. Is One Of These Not Like The Others?

Dobesh PP, Fanikos J.

J Atr Fibrillation. 2016 Aug 31;9(2):1481. doi: 10.4022/jafib.1481. eCollection 2016 Aug-Sep. Review.

8.

Association between antithrombotic treatment and hemorrhagic stroke in patients with atrial fibrillation-a cohort study in primary care.

Wändell P, Carlsson AC, Holzmann M, Ärnlöv J, Johansson SE, Sundquist J, Sundquist K.

Eur J Clin Pharmacol. 2017 Feb;73(2):215-221. doi: 10.1007/s00228-016-2152-8. Epub 2016 Nov 8.

9.

Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation.

Bahit MC, Lopes RD, Wojdyla DM, Held C, Hanna M, Vinereanu D, Hylek EM, Verheugt F, Goto S, Alexander JH, Wallentin L, Granger CB.

Heart. 2017 Apr;103(8):623-628. doi: 10.1136/heartjnl-2016-309901. Epub 2016 Oct 24.

10.

Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting.

Cannon CP, Gropper S, Bhatt DL, Ellis SG, Kimura T, Lip GY, Steg PG, Ten Berg JM, Manassie J, Kreuzer J, Blatchford J, Massaro JM, Brueckmann M, Ferreiros Ripoll E, Oldgren J, Hohnloser SH; RE-DUAL PCI Steering Committee and Investigators.

Clin Cardiol. 2016 Oct;39(10):555-564. doi: 10.1002/clc.22572. Epub 2016 Aug 26.

11.

Net clinical benefit of warfarin in individuals with atrial fibrillation across stroke risk and across primary and secondary care.

Allan V, Banerjee A, Shah AD, Patel R, Denaxas S, Casas JP, Hemingway H.

Heart. 2017 Feb;103(3):210-218. doi: 10.1136/heartjnl-2016-309910. Epub 2016 Aug 31.

12.

Systematic review and network meta-analysis of stroke prevention treatments in patients with atrial fibrillation.

Tawfik A, Bielecki JM, Krahn M, Dorian P, Hoch JS, Boon H, Husereau D, Pechlivanoglou P.

Clin Pharmacol. 2016 Aug 11;8:93-107. doi: 10.2147/CPAA.S105165. eCollection 2016.

13.

Risk impact of edoxaban in the management of stroke and venous thromboembolism.

Hurst KV, O'Callaghan JM, Handa A.

Vasc Health Risk Manag. 2016 Aug 11;12:329-35. doi: 10.2147/VHRM.S94679. eCollection 2016. Review.

14.

Newer Oral Anticoagulants: Stroke Prevention and Pitfalls.

Patel A, Goddeau RP Jr, Henninger N.

Open Cardiovasc Med J. 2016 May 27;10:94-104. doi: 10.2174/1874192401610010094. eCollection 2016.

15.
16.

Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL.

Freeman JV, Hutton DW, Barnes GD, Zhu RP, Owens DK, Garber AM, Go AS, Hlatky MA, Heidenreich PA, Wang PJ, Al-Ahmad A, Turakhia MP.

Circ Arrhythm Electrophysiol. 2016 Jun;9(6). pii: e003407. doi: 10.1161/CIRCEP.115.003407.

17.

Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial.

Jaspers Focks J, Brouwer MA, Wojdyla DM, Thomas L, Lopes RD, Washam JB, Lanas F, Xavier D, Husted S, Wallentin L, Alexander JH, Granger CB, Verheugt FW.

BMJ. 2016 Jun 15;353:i2868. doi: 10.1136/bmj.i2868.

18.

Anticoagulation and population risk of stroke and death in incident atrial fibrillation: a population-based cohort study.

Yu AY, Malo S, Wilton S, Parkash R, Svenson LW, Hill MD.

CMAJ Open. 2016 Jan 7;4(1):E1-6. doi: 10.9778/cmajo.20150096. eCollection 2016 Jan-Mar.

19.

Effect of Left Ventricular Systolic Dysfunction on Response to Warfarin.

Ather S, Shendre A, Beasley TM, Brown T, Hill CE, Prabhu SD, Limdi NA.

Am J Cardiol. 2016 Jul 15;118(2):232-6. doi: 10.1016/j.amjcard.2016.04.047. Epub 2016 May 5.

20.

Using an Atrial Fibrillation Decision Support Tool for Thromboprophylaxis in Atrial Fibrillation: Effect of Sex and Age.

Eckman MH, Lip GY, Wise RE, Speer B, Sullivan M, Walker N, Kissela B, Flaherty ML, Kleindorfer D, Baker P, Ireton R, Hoskins D, Harnett BM, Aguilar C, Leonard A, Arduser L, Steen D, Costea A, Kues J.

J Am Geriatr Soc. 2016 May;64(5):1054-60. doi: 10.1111/jgs.14099.

Supplemental Content

Loading ...
Support Center